For life sciences companies navigating patient assistance or cost-sharing arrangements, this opinion adds important clarity particularly for innovative products caught in the gap between FDA approval and USPSTF coverage recommendations
Int J Obes (Lond) 38(6):784793 Hoffman S, Adeli K (2021) Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
A reputable online clinic offering GLP-1/GIP weight loss therapy should provide the following: Licensed provider oversight: A board-certified or licensed clinician who reviews your health history, assesses eligibility, and prescribes medication Pharmacy-dispensed medication: Prescriptions filled by licensed U.S
An Eli Lilly spokesperson said: We expect Zepbound to be used as part of an ongoing disease management strategy for adults with obesity, in addition to a reduced-calorie diet and increased physical activity. The FDA told Fortune that it regulates the marketing and distribution of prescription drugs, and that companies are responsible for not misleading customers and being truthful in their product marketing, but the agency declined to comment on any specific companies and whether it had investigated or issued any warnings, noting that the FDA generally does not comment on pending or potential compliance matters. We wanted to make sure that we stayed on message Calibrate was one of the first weight-loss companies to enter what has become a saturated space
Based on PSGs Artemetrx analysis for the calendar year 2023, we observed 50% of patients adherent to Ozempic (defined as a proportion of days (PDC) greater than or equal to eighty percent)and an overall PDC of 68%, compared to an adherence rate of 42% and PDC of 60% for Wegovy
The FDA checks new treatments through strict clinical trials
